Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe
leading to significantly higher risk for premature heart disease in those affected. As treatment …

Predictive genetic testing can provide information about whether or not someone will
develop or is likely to develop a specific condition at a later stage in life. Economic …

Familial hypercholesterolemia (FH) is a common, inherited disorder of cholesterol
metabolism. This pathology is usually an autosomal dominant disorder and is caused by …

Background and aims There are no studies that have specifically investigated the cost-
effectiveness of cascade screening of children for heterozygous familial …

Background Population genomic screening for familial hypercholesterolemia (FH) in
unselected individuals can prevent premature cardiovascular disease. Objective To estimate …

Genomic medicine is expanding from a focus on diagnosis at the patient level to prevention
at the population level given the ongoing under-ascertainment of high-risk and actionable …

Detection of familial hypercholesterolemia can be enhanced by optimizing current
diagnostic algorithms, probing electronic health records with novel information technologies …

Background and aims The prevalence of familial hypercholesterolemia (FH) is high among
patients with stable coronary artery disease (CAD). However, data on FH on admission …

AIMS Diagnosis rate of familial hypercholesterolemia (FH) remained less than 10% globally
and the economic evaluation results of different FH screening strategies varied. This study …